氢吗啡酮应用于骨科患者术后镇痛的研究进展
Research Progress in the Application of Hydromorphone to Postoperative Analgesia in Orthopaedic Patients
DOI: 10.12677/acm.2024.1492533, PDF,   
作者: 李雪荣:内蒙古医科大学附属医院麻醉科,内蒙古 呼和浩特
关键词: 氢吗啡酮骨科加速康复多模式镇痛情绪Hydromorphone Orthopedic Accelerated Recovery Multimodal Analgesia Emotions
摘要: 镇痛是骨科患者术后康复中不可或缺的一环,不仅仅是减轻疼痛的关键,也是术后加速康复(ERAS)的重要环节。目前,在骨科手术术后有多种镇痛模式可供选择,包括连续硬膜外镇痛、连续外周神经阻滞镇痛以及患者自控镇痛等。镇痛药物类别丰富,应用最广的当属阿片类药物,氢吗啡酮作为吗啡的半合成衍生物,相比吗啡,能更快缓解疼痛,镇痛强度更高,副作用更少等特点。在骨科患者术后逐渐显示出它独特的镇痛优势,本文旨在综述氢吗啡酮在不同类型镇痛模式下的有效性,并促进其应用于骨科患者镇痛,加速骨科患者术后康复,提高患者镇痛满意度。
Abstract: Analgesia is an indispensable part of postoperative recovery of orthopaedic patients, which is not only the key to reduce pain, but also an important part of enhance recovery after surgery (ERAS). At present, there are a variety of analgesia modes to choose after orthopedic surgery, including continuous epidural analgesia, continuous peripheral nerve block analgesia, and patient-controlled analgesia. There are various types of analgesic drugs, and the most widely used ones are opioids. Hydromorphone, as a semi-synthetic derivative of morphine, has the characteristics of faster onset, stronger analgesic effject and fewer adverse reactions. It gradually shows its unique analgesic advantages in orthopaedic patients after surgery. This paper aims to review the effectiveness of hydromorphone in different types of analgesic modes, and promote its application in orthopaedic patients, enhance postoperative recovery of orthopaedic patients, and improve patients’ satisfaction with analgesia.
文章引用:李雪荣. 氢吗啡酮应用于骨科患者术后镇痛的研究进展[J]. 临床医学进展, 2024, 14(9): 806-811. https://doi.org/10.12677/acm.2024.1492533

参考文献

[1] Echeverria-Villalobos, M., Stoicea, N., Todeschini, A.B., Fiorda-Diaz, J., Uribe, A.A., Weaver, T., et al. (2019) Enhanced Recovery after Surgery (ERAS): A Perspective Review of Postoperative Pain Management under ERAS Pathways and Its Role on Opioid Crisis in the United States. The Clinical Journal of Pain, 36, 219-226. [Google Scholar] [CrossRef] [PubMed]
[2] Hong, D., Flood, P. and Diaz, G. (2008) The Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia. Anesthesia & Analgesia, 107, 1384-1389. [Google Scholar] [CrossRef] [PubMed]
[3] Felden, L., Walter, C., Harder, S., Treede, R., Kayser, H., Drover, D., et al. (2011) Comparative Clinical Effects of Hydromorphone and Morphine: A Meta-Analysis. British Journal of Anaesthesia, 107, 319-328. [Google Scholar] [CrossRef] [PubMed]
[4] Bhalla, T., DiGiusto, M., Martin, D., Jones, M., Tobias, J. and Foerschler, D. (2014) Patient-Controlled Analgesia in the Pediatric Population: Morphine versus Hydromorphone. Journal of Pain Research, 7, 471-475. [Google Scholar] [CrossRef] [PubMed]
[5] Olson, K.M., Duron, D.I., Womer, D., Fell, R. and Streicher, J.M. (2019) Comprehensive Molecular Pharmacology Screening Reveals Potential New Receptor Interactions for Clinically Relevant Opioids. PLOS ONE, 14, e0217371. [Google Scholar] [CrossRef] [PubMed]
[6] Yang, Y., Wu, J., Li, H., Ye, S., Xu, X., Cheng, L., et al. (2018) Prospective Investigation of Intravenous Patient-Controlled Analgesia with Hydromorphone or Sufentanil: Impact on Mood, Opioid Adverse Effects, and Recovery. BMC Anesthesiology, 18, Article No. 37. [Google Scholar] [CrossRef] [PubMed]
[7] Saari, T.I., Ihmsen, H., Mell, J., Fröhlich, K., Fechner, J., Schüttler, J., et al. (2014) Influence of Intensive Care Treatment on the Protein Binding of Sufentanil and Hydromorphone during Pain Therapy in Postoperative Cardiac Surgery Patients. British Journal of Anaesthesia, 113, 677-687. [Google Scholar] [CrossRef] [PubMed]
[8] Lussier, D., Richarz, U. and Finco, G. (2010) Use of Hydromorphone, with Particular Reference to the OROS® Formulation, in the Elderly. Drugs & Aging, 27, 327-335. [Google Scholar] [CrossRef] [PubMed]
[9] Vandenbossche, Richarz, and Richards, H. (2012) Repeat-Dose Steady-State Pharmacokinetic Evaluation of Once-Daily Hydromorphone Extended-Release (OROS® Hydromorphone ER) in Patients with Chronic Pain. Journal of Pain Research, 5, 523-533. [Google Scholar] [CrossRef] [PubMed]
[10] Owsiany, M.T., Hawley, C.E., Triantafylidis, L.K. and Paik, J.M. (2019) Opioid Management in Older Adults with Chronic Kidney Disease: A Review. The American Journal of Medicine, 132, 1386-1393. [Google Scholar] [CrossRef] [PubMed]
[11] Wright, A.W.E., Mather, L.E. and Smith, M.T. (2001) Hydromorphone-3-Glucuronide: A More Potent Neuro-Excitant than Its Structural Analogue, Morphine-3-Glucuronide. Life Sciences, 69, 409-420. [Google Scholar] [CrossRef] [PubMed]
[12] 邢飞. 脊髓CXCL12/CXCR4信号通路介导大鼠术后痛的分子机制[D]: [硕士学位论文]. 郑州: 郑州大学, 2017.
[13] Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F. and Lagane, B. (2009) CXCR7 Heterodimerizes with CXCR4 and Regulates Cxcl12-Mediated G Protein Signaling. Blood, 113, 6085-6093. [Google Scholar] [CrossRef] [PubMed]
[14] Kehlet, H. (1997) Multimodal Approach to Control Postoperative Pathophysiology and Rehabilitation. British Journal of Anaesthesia, 78, 606-617. [Google Scholar] [CrossRef] [PubMed]
[15] Kehlet, H. (1989) Surgical Stress: The Role of Pain and Analgesia. British Journal of Anaesthesia, 63, 189-195. [Google Scholar] [CrossRef] [PubMed]
[16] 张艳. 氢吗啡酮与舒芬太尼静脉自控镇痛对骨科老年患者术后镇痛、谵妄的影响对比[J]. 实用中西医结合临床, 2023, 23(5): 61-64.
[17] 甘育涛, 陈佳青, 彭攀. 氢吗啡酮与布托啡诺静脉自控镇痛对骨科术后患者疼痛递质、炎性因子及氧化应激反应的影响比较[J]. 临床合理用药, 2023, 16(21): 114-117.
[18] 黄甜甜, 李国振, 李勇. 盐酸氢吗啡酮用于骨科术后硬膜外自控镇痛的有效性研究[J]. 中国实用医药, 2023, 18(9): 113-115.
[19] 戴逸骅. 盐酸氢吗啡酮用于骨科术后硬膜外自控镇痛[J]. 中国社区医师, 2020, 36(30): 23-24.
[20] 孙雪峰, 庞博. 连续股神经阻滞联合盐酸氢吗啡酮在全膝关节置换术后的镇痛效果[J]. 海峡药学, 2020, 32(2): 140-141.
[21] 戴海新, 王强, 黄继东. 不同剂量盐酸氢吗啡酮关节腔内注射在老年膝关节镜术后镇痛的应用[J]. 河南医学高等专科学校学报, 2021, 33(6): 694-696.
[22] Crile, G.W. and Lower, W.E. (1914) Anoci Association. Saunders, 223-225.
[23] 王彦强, 罗远国. 氢吗啡酮超前镇痛对股骨骨折患者术后应激反应、炎性因子及认知功能的影响[J]. 中国医学前沿杂志(电子版), 2017, 9(6): 43-46.
[24] 陈三冬, 魏峥, 王帅. 氢吗啡酮复合罗哌卡因用于小儿术后镇痛的有效性和安全性[J]. 医药论坛杂志, 2024(10): 1087-1090.
[25] Rapp, S.E., Egan, K.J., Ross, B.K., Wild, L.M., Terman, G.W. and Ching, J.M. (1996) A Multidimensional Comparison of Morphine and Hydromorphone Patient-Controlled Analgesia. Anesthesia & Analgesia, 82, 1043-1048. [Google Scholar] [CrossRef
[26] Puryear, C.B., Brooks, J., Tan, L., Smith, K., Li, Y., Cunningham, J., et al. (2020) Opioid Receptor Modulation of Neural Circuits in Depression: What Can Be Learned from Preclinical Data? Neuroscience & Biobehavioral Reviews, 108, 658-678. [Google Scholar] [CrossRef] [PubMed]
[27] Vander Weele, C.M., Porter‐Stransky, K.A., Mabrouk, O.S., Lovic, V., Singer, B.F., Kennedy, R.T., et al. (2014) Rapid Dopamine Transmission within the Nucleus Accumbens: Dramatic Difference between Morphine and Oxycodone Delivery. European Journal of Neuroscience, 40, 3041-3054. [Google Scholar] [CrossRef] [PubMed]
[28] Margolis, E.B., Fujita, W., Devi, L.A. and Fields, H.L. (2017) Two Delta Opioid Receptor Subtypes Are Functional in Single Ventral Tegmental Area Neurons, and Can Interact with the Mu Opioid Receptor. Neuropharmacology, 123, 420-432. [Google Scholar] [CrossRef] [PubMed]